NCT05705791View on ClinicalTrials.gov

Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

QuiremSpheres

166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy

Trial Locations (6)

21000

Centre Georges-François Leclerc, Dijon

CHU François Mitterand, Dijon

34000

Hôpital Saint Eloi, Montpellier

44000

CHU Nantes, Nantes

92110

AP-HP Hôpital Beaujon, Clichy

94800

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER